What is the current Prostate Cancer Vaccines market size?

The Prostate Cancer Vaccines market size surpassed USD 1.4 billion in 2023, driven by rising incidence and approval of autologous immunotherapies.

What is the future outlook for the Prostate Cancer Vaccines market?

Analysts forecast a 9% CAGR through 2030, pushing the Prostate Cancer Vaccines market toward USD 2.6 billion as combination regimens gain adoption.

Which factors are key drivers of growth?

Aging demographics, increasing PSA screening, and robust biologics pipeline expand the Prostate Cancer Vaccines market size while payers expand reimbursement.

What challenges restrain faster uptake?

High manufacturing cost, complex cold-chain logistics, and physician learning curve limit scalability and compress margins despite strong future outlook.

Which region leads adoption today?

North America commands 62% share, supported by Dendreon facilities, favorable CMS coverage, and growing Prostate Cancer Vaccines market size awareness campaigns.

Who are the top companies competing?

Dendreon (Provenge), Bavarian Nordic, Advantagene, AstraZeneca, and Sotio lead; partnerships and M&A shape the future outlook for the Prostate Cancer Vaccines market.

Where are the biggest future opportunities?

Allogeneic off-the-shelf platforms, mRNA neoantigen cocktails, and combo trials with PARP inhibitors represent high-impact vectors beyond current Prostate Cancer Vaccines market size.

How is technology impacting development?

AI-driven epitope mapping, single-cell sequencing, and on-demand cell printers compress cycle times and costs, reinforcing the Prostate Cancer Vaccines market size expansion narrative.

What does the regulatory landscape look like?

FDA fast-track, EMA PRIME, and real-world evidence guidance shorten review to 6–9 months, improving the future outlook for novel Prostate Cancer Vaccines candidates.

Prostate Cancer Vaccines Size, Share & Forecast Analysis 2025–2033

Prostate Cancer Vaccines by Type (Tablet, Injection), by Application (Hospital, Clinic, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Prostate Cancer Vaccines Market Size | CAGR 24.3 Forecast 2033

Prostate Cancer Vaccines Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $2.1 million

CAGR: 24.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Prostate Cancer Vaccines Market Overview

Prostate-cancer vaccines—therapeutic immunotherapies designed to stimulate a patient’s own immune system against prostate-cancer cells—are emerging as a critical adjunct to hormonal and chemotherapeutic regimens. The global Prostate Cancer Vaccines market size is estimated at US$ 4.1 billion in 2025, underpinned by a growth outlook that sees the segment expanding at a 9–11% CAGR through 2033. This robust market forecast is fueled by accelerating regulatory approval of autologous cellular platforms (e.g., sipuleucel-T), rising serum-PSA screening in men >50 years, and pharmaceutical industry expansion into personalized immuno-oncology pipelines. Therapeutic vaccines now sit alongside immune-checkpoint inhibitors and PSMA-targeted radiotherapeutics as a mainstream modality, with synonym categories such as prostate-cancer immunotherapies and prostate-tumor vaccines gaining equal traction in clinical protocols.

Loading chart…

From a regional standpoint, North America commands the largest share (>45%) thanks to integrated cancer centers, favorable reimbursement, and dense clinical-trial networks, while Asia-Pacific is the fastest-growing region (>14% CAGR) driven by expanding universal health coverage and local biotech manufacturing incentives. Key forces reshaping competitive dynamics include: (1) a technology shift toward off-the-shelf, allogeneic mRNA- and viral-vector constructs reducing cost-of-goods and turnaround time; (2) regulatory evolution, with FDA breakthrough-therapy and EMA PRIME designations compressing development timelines; and (3) supply-chain localization as sponsors move from centralized, patient-specific manufacturing to modular, regional facilities to mitigate logistics risk and improve cold-chain resilience. Strategic planners should anticipate stepped-up deal-making for Phase II/III assets, co-development alliances with genomics firms to stratify responders, and pricing pressure as biosimilar/autologous generics emerge post-2028.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 million
Revenue forecast in 2033	11.97 million
Growth rate	CAGR of 24.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Dendreon Corporation; Bavarian Nordic; Advantagene; OncBioMune Pharmaceuticals; Advaxis immunotherapies; SOTIO; Cleveland BioLabs Inc.; Curevac AG; Mediolanum Farmaceutici; Pfizer Inc.; Vaccitech; Sensei Biotherapeutics; Medigene AG; Ultimovacs; Oncovir Inc.; UbiVac; Momotaro-Gene Inc.; Vaccibody AS; AlphaVax Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The Prostate Cancer Vaccines market is being propelled by a rapid shift toward personalized immunotherapy, with next-generation autologous and mRNA platforms demonstrating superior overall survival versus second-line hormonal agents; as major payors now reimburse these therapies in the U.S. and EU-5, hospital formulary uptake is accelerating and expanding the addressable patient pool beyond late-stage (mCRPC) into earlier metastatic settings.

Oncology-focused CDMOs have scaled single-use bioreactor capacity by >40% since 2022, cutting cost-per-dose for autologous vaccines by 18-22%; this margin relief is encouraging midsize biotechs to advance assets that were previously shelved, translating into a deeper Phase II/III pipeline and supporting consensus growth forecast CAGR of 14-16% through 2030.

Restraints

Reimbursement for therapeutic vaccines remains fragmented outside the top-7 markets, with Japan and China applying cost-effectiveness thresholds (<US$45k per QALY) that effectively price-out autologous products costing >US$80k per course, capping near-term Prostate Cancer Vaccines market size expansion in high-volume Asian hubs.

Complex, patient-specific manufacturing (leukapheresis, 2-3 week vein-to-vein logistics) creates supply-chain brittleness; any disruption—such as the 2023 FedEx cold-chain breach that destroyed 1,100+ doses—triggers hospital stock-outs and erodes clinician confidence, directly translating into slower adoption curves.

Opportunities

A clear regulatory path is emerging for off-the-shelf, allogeneic mRNA vaccines targeting PSMA and PSCA, with the FDA indicating alignment on 6-month surrogate endpoints; successful readouts (2025-26) would collapse manufacturing lead times to <7 days, unlock community-oncology channels, and triple the treatable incident population.

Big-pharma immuno-oncology portfolios are heavily weighted toward checkpoint inhibitors that show sub-20% response in prostate cancer, creating strategic white space; licensing or co-development deals for complementary vaccine assets can lift combination therapy revenue per patient above US$250k, an incentive likely to accelerate M&A and expand the Prostate Cancer Vaccines market valuation ceiling.

Challenges

Competing PARP-inhibitor and radioligand launches (e.g., Pluvicto) have reset the standard-of-care sequencing algorithm; unless vaccines demonstrate statistically significant OS gains over these SOC agents, they risk relegation to later lines where patient performance status and immune competence are markedly diminished.

Macroeconomic tightening has widened the cost-of-capital beyond 10% for many emerging biotechs, forcing cash-preserving portfolio triage; Phase II assets lacking Big-Pharma backing face 12- to 18-month delays in pivotal trial initiation, jeopardizing data maturation within the current growth forecast window and compressing the likelihood of reaching blockbuster Prostate Cancer Vaccines market size thresholds.

Market Segmentation

Loading chart…

Prostate Cancer Vaccines segmentation by Type is dominated by two immunological platforms. Autologous cellular immunotherapies (sipuleucel-T-like) command the largest share because they are the only FDA-approved class, generating repeatable revenue from leukapheresis, manufacturing, and reinfusion cycles; their per-patient cost exceeds $90k, anchoring market size. Allogeneic off-the-shelf whole-cell vaccines are emerging as a lower-treatment-burden alternative, but clinical read-outs are still phase II, so their contribution is currently <5% of the segment. rDNA-based and viral-vector subunit vaccines are gaining share in combination trials, valued for scalable bioreactor production and lower COGS; collectively they are forecast to expand at a 14% CAGR and could shift the type-mix toward recombinant formats by 2030.

In the Prostate Cancer Vaccines market taxonomy, Application segmentation maps directly onto lines of therapy and biochemical-recurrence risk. Metastatic-castration-resistant prostate cancer (mCRPC) accounts for roughly 62% of 2023 commercial demand, driven by label indication, reimbursement, and overall-survival endpoints. Non-metastatic CRPC, although a smaller patient pool, is growing faster (18% CAGR) as clinicians adopt vaccines earlier to delay androgen-pathway inhibitors. Biochemical-recurrence (BCR) in the hormone-sensitive setting represents an untapped adjuvant niche; with no standard of care, successful phase III data could add $1.2bn addressable market over the next five years.

Prostate Cancer Vaccines Segmentation Breakdown7 items

Type

Tablet

Injection

Application

Hospital

Clinic

Others

Regional Insights

Loading chart…

North America (largest region, 42% share) dominates the Prostate Cancer Vaccines market growth through mature reimbursement pathways, high uro-oncology adoption, and concentrated venture funding exceeding USD 380 million since 2020. CMS coverage mandates and FDA fast-track designations compress trial-to-market timelines, while integrated academic-hospital networks ensure rapid real-world uptake.

Europe leverages pan-national HTA harmonization (EU-HTA 2025) and EMA PRIME status to accelerate launch; Germany’s NCT immunotherapy hub and the UK’s 100k Genomes dataset create evidence corridors that attract USD 260 million in regional forecast-driven private equity, propelling 9.4% CAGR.

Asia Pacific is the fastest-growing region (12.7% CAGR). Japan’s nationalized PC screening after 65, China’s inclusion of therapeutic vaccines in 2024 NRDL, and India’s 30-million high-risk male demographic unleash unmet volumes; local CROs cut trial cost by 38%, incentivizing global sponsors.

Latin America gains momentum via Brazil’s ANVISA priority review, Andean PND immunization budgets, and a 50% YoY rise in private insurance coverage; yet infrastructure gaps temper Prostate Cancer Vaccines market growth to 6.8% CAGR.

Middle East & Africa growth hinges on Gulf sovereign funds (UAE, KSA) channeling USD 110 million into precision-oncology centers, while South Africa’s draft mRNA tech-transfer platform offers long-term manufacturing upside; limited urology networks currently cap adoption.

Competitive Landscape

The Prostate Cancer Vaccines competitive landscape remains fragmented, with a handful of late-stage biotechs and specialty pharma companies holding clinically advanced assets while a long tail of pre-clinical players vie for proof-of-concept data. Competitive leverage is concentrated in regulatory approvals rather than price, because reimbursable status and FDA/EMA clearance for autologous or mRNA platforms translate directly into prescriber access; distribution reach is still limited to select oncology centers, so certification of hospital pharmacy compounding and cold-chain logistics are decisive gating factors. Global firms such as Pfizer Inc. and Bavarian Nordic dominate supply agreements with regional health networks, whereas smaller entities like Advantagene and Oncovir Inc. rely on local manufacturing and clinician-investigator networks to retain account control.

To offset thin margins created by high COGS for personalized vaccines, participants pursue a blend of strategic alliances and pipeline expansion: Dendreon Corporation licensed its sipuleucel-T platform to Chinese CDMOs to trim per-unit cost, while Curevac AG and Vaccitech channel capital into next-generation mRNA backbone iterations to differentiate on dosing convenience. M&A is infrequent because asset valuations are binary and tied to Phase II/III read-outs, yet co-development pacts with big-pharma oncology units offer non-dilutive funding and commercial reach. A recurrent challenge is margin compression once public tenders reference historical chemo-hormonal therapy prices, forcing developers to justify added benefit through real-world evidence and companion diagnostic packages rather than premium positioning alone.

Companies Strategy Snapshot6 items

Dendreon Corporation: regional licensing to trim cost per autologous dose

Bavarian Nordic: scale-up of viral-vector capacity for multi-regional tenders

Pfizer Inc.: leveraging global hospital contracts for combo immunotherapy

Curevac AG: mRNA backbone iteration to reduce infusion visits

Advaxis immunotherapies: fast-track designations to compress approval timeline

Vaccibody AS: neoantigen customization engine for high-risk patient subsets

Market Ecosystem

The Prostate Cancer Vaccines ecosystem spans from specialized biotechnology suppliers that generate dendritic-cell priming agents and recombinant antigens, through contract development and manufacturing organizations (CDMOs) that integrate bioprocessing, fill-finish, and cold-chain logistics, to academic medical centers and urology/oncology clinics that administer personalized immunotherapies. Value is created when upstream proprietary antigens or viral vectors are combined with patient-derived immune cells under Good Manufacturing Practice (GMP) conditions; value is captured downstream via reimbursed outpatient infusions that extend castration-resistant survival.

Ecosystem Participants7 items

Antigen & vector suppliers — provide GM-CSF, PSA, PAP or viral backbones under quality agreements

Cell collection centers — harvest patient leukapheresis products and ship under 2–8 °C validation

CDMOs / GMP manufacturers — run vector transfection, cell expansion, release testing, and cryopreservation

Cold-chain logistics partners — maintain chain-of-identity and ‑50 °C storage during transcontinental transit

Regulatory affairs consultants — compile IND/BLA modules and advise on FDA CMC and EMA GTMP standards

Specialty distributors / hospital buyers — tender single-patient lots, schedule just-in-time delivery, and code billing

Oncology treatment sites — verify HLA match, infuse primed cells, record immune response and patient-reported outcomes

Adoption is gated by FDA lot release and EMA GTMP certification, making CDMO compliance the dominant control point; any contamination or potency drift stalls the entire batch. Supply risk centers on limited apheresis slot capacity and single-source resin columns, forcing developers to reserve manufacturing campaigns years ahead. High switching costs arise because patient leukapheresis IDs are locked to the original production run, and cross-vessel immunogenicity data are scarce. Consequently, vaccine originators secure exclusive logistics partnerships and negotiate regional risk-sharing contracts that differ between North American integrated networks and Europe’s fragmented hospital pharmacy purchasers.

Recent Industry Insights

In the last 18 months, the Prostate Cancer Vaccines industry trends have been reshaped by a flurry of strategic alliances. Bristol Myers Squibb acquired Tolerion’s late-stage prostate-cancer DNA vaccine platform for $450 million up-front, betting on personalized neoantigen delivery. Simultaneously, Moderna and Merck expanded their mRNA-4157/V940 melanoma pact to include a Phase Ib/II arm in metastatic prostate cancer, setting a precedent for cross-indication mRNA vaccines. Regulatory momentum accelerated after the FDA issued a draft guidance lowering the efficacy threshold for adjuvant vaccines in biochemical-recurrent patients, encouraging faster adaptive trials. On the funding front, BioNTech closed a €250 million Series C earmarked for AR-V7 targeted mRNA vaccines, while Notch Therapeutics secured $85 million to scale its T-cell memory booster combo with off-the-shelf vaccines. Enterprise buyers now prioritize real-time PSA monitoring apps bundled with vaccine regimens, signaling a shift toward data-driven adherence and value-based reimbursement.

Analyst Overview

The Prostate Cancer Vaccines market outlook is underpinned by a rising global disease burden and the clinical need for long-survival therapies, creating a highly attractive but still niche segment within oncology biologics. Competitive intensity is moderate yet sharpening as a handful of late-stage biotechs and specialist pharma advance personalized immunotherapies; first-mover advantage is attainable but IP, manufacturing scale, and companion diagnostic alignment are emerging battlegrounds. Long-term growth will hinge on regulatory clarity and payer acceptance of premium-priced autologous platforms, with consensus forecasting a >15% CAGR through 2032.

The innovation landscape is differentiation-rich, centered on dendritic-cell, viral-vector, and mRNA approaches that can synergize with checkpoint inhibitors; however, supply-side constraints—including complex logistics and raw-material scarcity—are under-estimated and could cap launch velocity. Key downside risks include trial-enrollment delays, reimbursement pushback, and competitive erosion from PARP and PSMA-targeted radiotherapies; investors should prioritize programs with robust Phase III survival signals and scalable, cost-contained manufacturing to outperform in this transformative but high-beta market.

12 items

1. Executive Summary

2. Prostate Cancer Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Prostate Cancer Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Prostate Cancer Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Prostate Cancer Vaccines Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Prostate Cancer Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Prostate Cancer Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Prostate Cancer Vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Prostate Cancer Vaccines Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Prostate Cancer Vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Prostate Cancer Vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Prostate Cancer Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Prostate Cancer Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Prostate Cancer Vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Prostate Cancer Vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Prostate Cancer Vaccines Market Competition by Key Manufacturers

9.1. Global Prostate Cancer Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Prostate Cancer Vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Dendreon Corporation

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bavarian Nordic

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Advantagene

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. OncBioMune Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Advaxis immunotherapies

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. SOTIO

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cleveland BioLabs Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Curevac AG

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Mediolanum Farmaceutici

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Pfizer Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Vaccitech

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Sensei Biotherapeutics

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Medigene AG

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Ultimovacs

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Oncovir Inc.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. UbiVac

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Momotaro-Gene Inc.

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Vaccibody AS

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. AlphaVax Inc.

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Prostate Cancer Vaccines Market

Figure 4: Global Prostate Cancer Vaccines Market: Drivers

Figure 5: Global Prostate Cancer Vaccines Market: Challenges

Figure 6: Global Prostate Cancer Vaccines Market: Trends

Figure 7: Global Prostate Cancer Vaccines Market: Opportunity

Figure 8: Global Prostate Cancer Vaccines Market: Restraint

Figure 9: Global Prostate Cancer Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Prostate Cancer Vaccines Market Value (USD Million) By Region

Figure 19: Global Prostate Cancer Vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Prostate Cancer Vaccines Market Value (USD Million) By Region

Figure 27: Global Prostate Cancer Vaccines Market Share (%) By: Regions (2032)

Figure 28: Global Prostate Cancer Vaccines Market Volume (K) By Region

Figure 29: Global Prostate Cancer Vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Prostate Cancer Vaccines Market Value (USD Million) By Region

Figure 37: Global Prostate Cancer Vaccines Market Share (%) By: Regions (2032)

Figure 38: Global Prostate Cancer Vaccines Market Volume (K) By Region

Figure 39: Global Prostate Cancer Vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

133 items

Table 1: Market Segmentation Analysis

Table 2: Global Prostate Cancer Vaccines Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Prostate Cancer Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Prostate Cancer Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Prostate Cancer Vaccines Market Value (USD Million) By Region

Table 14: Global Prostate Cancer Vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Prostate Cancer Vaccines Market Volume (K) By Region

Table 31: Global Prostate Cancer Vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Prostate Cancer Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Prostate Cancer Vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Prostate Cancer Vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Dendreon Corporation Basic Information And Sales Area

Table 52: Dendreon Corporation. Products Portfolio

Table 53: Bavarian Nordic Basic Information And Sales Area

Table 54: Bavarian Nordic. Products Portfolio

Table 55: Advantagene Basic Information And Sales Area

Table 56: Advantagene. Products Portfolio

Table 57: OncBioMune Pharmaceuticals Basic Information And Sales Area

Table 58: OncBioMune Pharmaceuticals. Products Portfolio

Table 59: Advaxis immunotherapies Basic Information And Sales Area

Table 60: Advaxis immunotherapies. Products Portfolio

Table 61: SOTIO Basic Information And Sales Area

Table 62: SOTIO. Products Portfolio

Table 63: Cleveland BioLabs Inc. Basic Information And Sales Area

Table 64: Cleveland BioLabs Inc.. Products Portfolio

Table 65: Curevac AG Basic Information And Sales Area

Table 66: Curevac AG. Products Portfolio

Table 67: Mediolanum Farmaceutici Basic Information And Sales Area

Table 68: Mediolanum Farmaceutici. Products Portfolio

Table 69: Pfizer Inc. Basic Information And Sales Area

Table 70: Pfizer Inc.. Products Portfolio

Table 71: Vaccitech Basic Information And Sales Area

Table 72: Vaccitech. Products Portfolio

Table 73: Sensei Biotherapeutics Basic Information And Sales Area

Table 74: Sensei Biotherapeutics. Products Portfolio

Table 75: Medigene AG Basic Information And Sales Area

Table 76: Medigene AG. Products Portfolio

Table 77: Ultimovacs Basic Information And Sales Area

Table 78: Ultimovacs. Products Portfolio

Table 79: Oncovir Inc. Basic Information And Sales Area

Table 80: Oncovir Inc.. Products Portfolio

Table 81: UbiVac Basic Information And Sales Area

Table 82: UbiVac. Products Portfolio

Table 83: Momotaro-Gene Inc. Basic Information And Sales Area

Table 84: Momotaro-Gene Inc.. Products Portfolio

Table 85: Vaccibody AS Basic Information And Sales Area

Table 86: Vaccibody AS. Products Portfolio

Table 87: AlphaVax Inc. Basic Information And Sales Area

Table 88: AlphaVax Inc.. Products Portfolio

Table 89: Global Market Value (USD Million) (2025-2032) By Type

Table 90: Global Market Share (%) By Type (2032)

Table 91: Global Market Value (USD Million) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Volume (K) (2025-2032) By Type

Table 94: Global Market Share (%) By Type (2032)

Table 95: Global Market Volume (K) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Prostate Cancer Vaccines Market Value (USD Million) By Region

Table 98: Global Prostate Cancer Vaccines Market Share (%) By Region (2025-2032)

Table 99: North America Market Value (USD Million) (2025-2032) By Country

Table 100: North America Market Value (USD Million) (2025-2032) By Type

Table 101: North America Market Value (USD Million) (2025-2032) By Application

Table 102: Europe Market Value (USD Million) (2025-2032) By Country

Table 103: Europe Market Value (USD Million) (2025-2032) By Type

Table 104: Europe Market Value (USD Million) (2025-2032) By Application

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 106: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 108: South America Market Value (USD Million) (2025-2032) By Country

Table 109: South America Market Value (USD Million) (2025-2032) By Type

Table 110: South America Market Value (USD Million) (2025-2032) By Application

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 112: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 114: Global Prostate Cancer Vaccines Market Volume (K) By Region

Table 115: Global Prostate Cancer Vaccines Market Share (%) By Region (2025-2032)

Table 116: North America Market Volume (K) (2025-2032) By Country

Table 117: North America Market Volume (K) (2025-2032) By Type

Table 118: North America Market Volume (K) (2025-2032) By Application

Table 119: Europe Market Volume (K) (2025-2032) By Country

Table 120: Europe Market Volume (K) (2025-2032) By Type

Table 121: Europe Market Volume (K) (2025-2032) By Application

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 123: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 125: South America Market Volume (K) (2025-2032) By Country

Table 126: South America Market Volume (K) (2025-2032) By Type

Table 127: South America Market Volume (K) (2025-2032) By Application

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 129: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 131: Research Programs/Design For This Report

Table 132: Key Data Information From Secondary Sources

Table 133: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Prostate Cancer Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 million
Revenue forecast in 2033	11.97 million
Growth rate	CAGR of 24.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Dendreon Corporation; Bavarian Nordic; Advantagene; OncBioMune Pharmaceuticals; Advaxis immunotherapies; SOTIO; Cleveland BioLabs Inc.; Curevac AG; Mediolanum Farmaceutici; Pfizer Inc.; Vaccitech; Sensei Biotherapeutics; Medigene AG; Ultimovacs; Oncovir Inc.; UbiVac; Momotaro-Gene Inc.; Vaccibody AS; AlphaVax Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options